Eli Lilly & Company (LLY US)

LLY US$1,288.30

20 minute delayed

Today ▲ 0.50%

1 year return ▲ 57.09%

Volume 536,084

Div yield 0.52%

PE ratio 43.25

52 week range

809.63 1,321.01

14 days free access

Join Market Matters and get full access to all our Opinion + Action

Learn more

Performance

Share price activity

Last (Price): 1,288.30
Change: ▲ 6.39 (0.50)
Bid / Ask: 0.00 - 0.00
Volume: 536,084
Turnover: 596,620,634
Open: 1,266.00
Day Range: 1,260.34 - 1,299.00
VWAP: 1,287.42
Prev Close: 1,281.91
Last Trade: 28/10 4:10pm

Key information

Sector: Healthcare
Shares Issued: 941,357,065
NTA/Share: 15.77
Last Dividend: 1.73
Dividend Ex Date: 14 AUG 2026
Dividend Pay Date: 10 SEP 2026

Current (USD) · FY2025

Revenue: 65,179.00
EBITDA: 27,728.00
Profit: 20,640.00
Earnings Per Share (EPS): 22.95
Dividend Per Share (DPS): 6.23
Yield %: 0.53
Market Cap: 1,148,335.31
Price to Earnings Ratio (P/E): 43.25

Estimates (USD) · FY2027

Revenue: 104,696.29
EBITDA: 55,141.75
Profit: 42,321.82
Earnings Per Share (EPS): 47.02
Dividend Per Share (DPS): 8.04

Quantitative rating

Overvalued

Economic Moat: Wide
Financial Health: Moderate
Uncertainty: High

Morningstar Quantitative Rating as of 21 OCT 2026.

Quantitative Equity Rating Methodology – view here

Fair value estimate

Five-star price 950.52 Fair value 1,125.80 One-star price 1,333.41

Morningstar Quantitative Rating as of 21 OCT 2026.

Quantitative valuation

Buy Sell

Fair Value: 1,125.80
Price / Fair Value: 1.13
Valuation: Overvalued
Uncertainty: High

Morningstar Quantitative Rating as of 21 OCT 2026. The slider runs from the five-star price (950.52) to the one-star price (1,333.41).

Ratios
Currency (Price/reporting): USD/USD
Exchange Rate: 1.0000

Price - closing or last bid	1,270.75
Price - 12 month high	1,311.22
Price - 12 month low	795.00
Pricing date	20 OCT 2026
Volume - avg. trading volume for the last ten days	2.39
Market capitalization	1,132,691.99
12 Month High price date	20 OCT 2026
12 Month Low price date	22 OCT 2025
Volume - avg. trading volume for the last 3 months	2.47
Price - 1 Day % Change	-1.01%
Price - 13 week price percent change	8.11%
Price - 26 week price percent change	40.72%
Price - 5 Day % Change	5.13%
Price - 52 week price percent change	58.93%
Price - YTD price percent change	17.69%
Price % Change Month To Date	9.09%

EPS excluding extraordinary items - most recent fiscal year	22.950
EPS excluding extraordinary items - trailing 12 month	29.790
EPS Normalized - most recent fiscal year	24.210
Revenue/share - most recent fiscal year	72.477
Revenue/share - trailing 12 month	88.853
Book value per share - most recent fiscal year	29.655
Book value per share - most recent quarter	38.002
Book value (tangible) per share - most recent fiscal year	15.774
Book value (tangible) per share - most recent quarter	7.762
Cash per share - most recent fiscal year	8.122
Cash per share - most recent quarter	10.039
Cash Flow per share - most recent fiscal year	27.695
Cash Flow per share - trailing 12 month	36.676
Dividend per share - most recent fiscal year	6.230
Dividends per share - trailing 12 month	6.690
EBITD per share - trailing 12 month	39.811
EPS Basic excluding extraordinary items - most recent fiscal year	23.000
EPS Basic excluding extraordinary items - trailing 12 month	29.840
EPS including extraordinary items - most recent fiscal year	23.000
EPS including extraordinary items - trailing 12 month	29.840
Free Cash Flow per share - trailing 12 month	20.477

P/E excluding extraordinary items, most recent fiscal year	42.66
P/E Normalized, most recent fiscal year	40.34
Price to sales - most recent fiscal year	14.30
Price to Tangible Book - most fiscal year	163.71
Price to Free Cash Flow per Share - most recent fiscal year	62.06
Price to Cash Flow per share - trailing 12 month	34.65
Price to Book - most recent fiscal year	33.44
P/E excluding extraordinary items high, trailing 12 months	54.38
P/E excluding extraordinary items low, trailing 12 months	33.20
Net Debt, LFI	45,958.00
Net Debt, LFY	35,235.00
Dividend Yield - 5 Year Average	0.76%
Dividend Yield - indicated annual dividend divided by closing price	0.52%
Current Dividend Yield - Common Stock Primary Issue, LTM	0.53%

Free Cash Flow - most recent fiscal year	14,057.00
LT debt/equity - most recent fiscal year	154.02%
Payout ratio - most recent fiscal year	27.15%
Total debt/total equity - most recent fiscal year	160.18%
LT debt/equity - most recent quarter	141.26%
Total debt/total equity - most recent quarter	162.07%
Free Cash Flow - trailing 12 month	18,359.80
Payout ratio - trailing 12 month	22.46%

Revenue - most recent fiscal year	65,179.00
Revenue - trailing 12 month	79,665.80
EBITD - most recent fiscal year	27,728.00
EBITD - trailing 12 month	35,694.30
Earnings before taxes - most recent fiscal year	25,731.00
Earnings before taxes - trailing 12 month	33,595.60
Net Income available to common - most recent fiscal year	20,640.00
Net Income available to common - trailing 12 months	26,711.20
Earnings before taxes Normalized - most recent fiscal year	29,571.00
Net Income Available to Common, Normalized - most recent fiscal year	21,768.00
Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM	31.50

Net Profit Margin % - 1st historical fiscal year	31.67%
Net Profit Margin % - trailing 12 month	33.53%
Operating margin - 1st historical fiscal year	45.56%
Operating margin - trailing 12 month	49.72%
Pretax margin - trailing 12 month	42.17%
Pretax margin - 1st historical fiscal year	39.48%
Operating Margin - 5 year average	33.93%
Pretax Margin - 5 year average	26.48%
Free Operating Cash Flow/Revenue, 5 Year Average	14.73%
Free Operating Cash Flow/Revenue, TTM	23.05%
Net Profit Margin - 5 year average	22.42%

Return on average assets - most recent fiscal year	20.79%
Return on average assets - trailing 12 month	22.74%
Return on average equity - most recent fiscal year	104.63%
Return on average equity - trailing 12 month	99.91%
Return on average assets - 5 year average	14.32%
Return on average equity - 5 year average	75.98%
Net Income/employee - most recent fiscal year	412,800.00
Revenue/employee - most recent fiscal year	1,303,580.00

Revenue growth rate, 5 year	21.58%
EPS growth rate, 5 year	27.58%
Growth rate% - dividend, 3 year	15.24%
Revenue/share (5 yr growth)	21.93%
Growth rate% - Revenue, 3 year	31.69%
Growth rate% - EPS, 3 year	49.27%
Book value per share growth rate, 5 year	38.13%
Capital Spending growth rate, 5 year	39.84%
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR	25.57%

Financial forecast (USD, millions except per share)

	Actuals	Estimates
	2025	2026	2027	2028	2029

Financials (USD, millions)

Period end:	DEC 21	DEC 22	DEC 23	DEC 24	DEC 25
Fiscal year:	2021	2022	2023	2024	2025
Period length:	12 months	12 months	12 months	12 months	12 months

Announcements

Announcements are available for ASX-listed companies only.

Opinion

08/08/2025 09:28

Eli Lilly & Co. (LLY US) $US640.86

We discussed LLY in detail in a recent report around weight loss drugs but the U.S. pharmaceutical company failed to live up to expectations overnight with the stock falling 13%, its worst session in 26 years, after late-stage trial results of its oral obesity pill disappointed investors. That’s despite the pharmaceutical giant posting better-than-expected second-quarter results and raising its full-year outlook; there's little doubt what the “hot money” has been focusing on:

31/07/2025 09:53

Eli Lilly & Co (LLY US) $760.08

Eli Lilly (LLY) is a leading U.S. pharmaceutical company best known for its blockbuster diabetes and weight-loss drug Mounjaro (Tirzepatide) and its new obesity drug Zepbound.

09/08/2024 09:30

Eli Lilly & Company (LLY US) $US845.31

Overnight pharmaceutical giant Eli Lilly surged 9.5% after posting better-than-expected earnings and raising its full-year outlook on strong demand for diabetes treatment Mounjaro and obesity drug Zepbound – a massive move for a $US800bn business. LLY reported 2nd quarter revenue that significantly outstripped expectations, plus they hiked the full-year revenue outlook by $3 billion.

27/09/2023 09:05

Eli Lily & Company (LLY US) $US550.01

Obesity is a global epidemic with 14% of the global adult population defined as obese (Body Mass Index BMI >30) while another 26% are overweight (BMI>25). As wealth increases, so do waistlines. This has been a topic of intense coverage over recent weeks following the results of a wide-ranging clinical trial from Denmark-based Novo Nordisk (NVO US), which showed that Semaglutide treatments used to treat type 2 diabetes had a significant impact on meaningful adverse cardiovascular events (MACE), essentially by suppressing appetite and prompting weight loss

Action

Updated 08/08/2025 17:31

LLY US

Updated 08/08/2025 17:31

MM is now neutral towards LLY

Read the opinion

Updated 31/07/2025 10:14

LLY US

Updated 31/07/2025 10:14

MM is cautiously bullish towards ELI

Read the opinion

Updated 09/08/2024 13:15

LLY US

Updated 09/08/2024 13:15

MM is bullish LLY US medium-term

Read the opinion

Updated 27/09/2023 09:29

LLY US

Updated 27/09/2023 09:29

MM is neutral LLY, targeting a ~10% pullback towards US$500

Read the opinion

Business Summary

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.